Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine.
Replication of retroviral and host genomes requires ribonucleotide reductase to convert rNTPs to dNTPs, which are then used as substrates for DNA synthesis. Inhibition of ribonucleotide reductase by hydroxyurea (HU) has been previously used to treat cancers as well as HIV. However, the use of HU as an antiretroviral is limited by its associated toxicities such as myelosuppression and hepatotoxicity. In this study, we examined the ribonucleotide reductase inhibitor, gemcitabine, both in cell culture and in C57Bl/6 mice infected with LP-BM5 murine leukemia virus (LP-BM5 MuLV, a murine AIDS model). Gemcitabine decreased infectivity of MuLV in cell culture with an EC50 in the low nanomolar range with no detectable cytotoxicity. Similarly, gemcitabine significantly decreased disease progression in mice infected with LP-BM5. Specifically, gemcitabine treatment decreased spleen size, plasma IgM, and provirus levels compared to LP-BM5 MuLV infected, untreated mice. Gemcitabine efficacy was observed at doses as low as 1 mg/kg/day in the absence of toxicity. Higher doses of gemcitabine (3 mg/kg/day and higher) were associated with toxicity as determined by a loss in body mass. In summary, our findings demonstrate that gemcitabine has antiretroviral activity ex vivo and in vivo in the LP-BM5 MuLV model. These observations together with a recent ex vivo study with HIV-1, suggest that gemcitabine has broad antiretroviral activity and could be particularly useful in vivo when used in combination drug therapy.
Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, United States of America.
Christine L
CL
Clouser
Colleen M
CM
Holtz
Mary
M
Mullett
Duane L
DL
Crankshaw
Jacquie E
JE
Briggs
Jay
J
Chauhan
Ilze Matise
IM
VanHoutan
Steven E
SE
Patterson
Louis M
LM
Mansky
D000818:Animals; D044966:Anti-Retroviral Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D018450:Disease Progression; D007075:Immunoglobulin M / Q000097:blood; D009052:Leukemia Virus, Murine / Q000187:drug effects*; D051379:Mice; D008810:Mice, Inbred C57BL; D016183:Murine Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors; D013154:Spleen / Q000473:pathology; D019562:Viral Load / Q000187:drug effects; D000093542:Gemcitabine
D044966:Anti-Retroviral Agents; D007075:Immunoglobulin M; D003841:Deoxycytidine; D012264:Ribonucleotide Reductases; D000093542:Gemcitabine
Blood. 1998 Nov 15;92(10):3780-92
9808572
Cell Mol Biol (Noisy-le-grand). 1997 Nov;43(7):1019-29
9449534
Mol Pharmacol. 1990 Oct;38(4):567-72
2233693
Proc Natl Acad Sci U S A. 1989 May;86(10):3862-6
2542949
PLoS Pathog. 2006 Mar;2(3):e25
16609730
J Virol. 1991 Aug;65(8):4232-41
1649328
J Biol Chem. 1992 Feb 25;267(6):3589-96
1371272
J Virol. 1989 Mar;63(3):1223-31
2536830
Methods. 1997 Aug;12(4):337-42
9245614
J Virol. 1993 Oct;67(10):5939-47
7690415
Science. 2009 Oct 23;326(5952):585-9
19815723
Antimicrob Agents Chemother. 1990 Apr;34(4):605-9
1693056
AIDS. 1992 Jul;6(7):607-21
1503680
J Exp Med. 1987 Jun 1;165(6):1737-42
3035057
Antivir Ther. 1999;4 Suppl 3:101-8
16021881
J Antimicrob Chemother. 2002 Nov;50(5):639-47
12407119
Drug Metab Rev. 2009;41(2):77-88
19514966
Arch Virol. 2010 Apr;155(4):601-5
20204428
J Exp Med. 1988 Aug 1;168(2):623-35
2842430
J Gastroenterol. 2006 Jan;41(1):70-6
16501860
Virology. 1997 Jun 23;233(1):193-8
9201229
J Virol. 2010 Sep;84(18):9301-9
20610712
FASEB J. 2008 Mar;22(3):659-61
17942826
Curr HIV Res. 2006 Oct;4(4):431-46
17073618
J Clin Microbiol. 2004 Sep;42(9):4361-4
15365045
J Med Chem. 2009 Nov 26;52(22):6958-61
19860433
Virology. 1995 Jan 10;206(1):555-63
7831810
Am J Pathol. 1982 Jun;107(3):362-77
6282131
Antiviral Res. 2002 Nov;56(2):167-81
12367722